DeepMed Research

Ohsu Knight Cancer Institute

🇺🇸United States

Country: 🇺🇸United States

Ownership: Subsidiary

Employees: -

Market Cap: -

Website: http://www.ohsu.edu/knight-cancer-institute

Clinical Trials

Standard Verbal Counseling With or Without a Pictorial Educational Tool for the Reduction of Psychological Morbidity in Patients With Stage 0-IIIA Breast Cancer Receiving Radiation Therapy, COPE Study

Not Applicable

Recruiting

Conditions: Prognostic Stage I Breast Cancer AJCC v8
Anatomic Stage I Breast Cancer AJCC v8
Anatomic Stage IB Breast Cancer AJCC v8
Prognostic Stage IIA Breast Cancer AJCC v8
Prognostic Stage IIIA Breast Cancer AJCC v8
Prognostic Stage II Breast Cancer AJCC v8
Anatomic Stage 0 Breast Cancer AJCC v8
Anatomic Stage IA Breast Cancer AJCC v8
Anatomic Stage II Breast Cancer AJCC v8
Anatomic Stage IIB Breast Cancer AJCC v8

Interventions: Other: Counseling
Behavioral: Questionnaire
Other: Educational Intervention

First Posted Date: 2021-08-06

Last Posted Date: 2024-12-05

Lead Sponsor: OHSU Knight Cancer Institute

Target Recruit Count: 60

Registration Number: NCT04993313

Locations: 🇺🇸
OHSU Knight Cancer Institute, Portland, Oregon, United States

Electronic Quitline Referral with Enhanced Academic Detailing for the Promotion of Smoking Cessation

Not Applicable

Conditions: Tobacco-Related Carcinoma
Smoking Cessation

Interventions: Behavioral: Enhanced Academic Detailing
Other: Informational Intervention

First Posted Date: 2021-07-21

Last Posted Date: 2025-03-05

Lead Sponsor: OHSU Knight Cancer Institute

Target Recruit Count: 10000

Registration Number: NCT04969978

Locations: 🇺🇸
OHSU Knight Cancer Institute, Portland, Oregon, United States

Endoscopic Botulinum Toxin Injection in the Prevention of Postoperative Pancreatic Fistula Following Distal Pancreatectomy

Phase 2

Terminated

Conditions: Pancreatic Carcinoma

Interventions: Biological: Botulinum Toxin Type A

First Posted Date: 2021-07-16

Last Posted Date: 2025-05-13

Lead Sponsor: OHSU Knight Cancer Institute

Target Recruit Count: 4

Registration Number: NCT04965311

Locations: 🇺🇸
OHSU Knight Cancer Institute, Portland, Oregon, United States

Decision Aid for the Improvement of Decision-Making in Patients With Non-small Cell Lung Cancer

Not Applicable

Active, not recruiting

Conditions: Stage IV Lung Cancer AJCC v8
Stage III Lung Cancer AJCC v8
Stage I Lung Cancer AJCC v8
Stage II Lung Cancer AJCC v8
Lung Non-Small Cell Carcinoma

Interventions: Other: Informational Intervention
Other: Best Practice
Other: Questionnaire Administration

First Posted Date: 2021-06-30

Last Posted Date: 2025-03-11

Lead Sponsor: OHSU Knight Cancer Institute

Target Recruit Count: 98

Registration Number: NCT04946279

Locations: 🇺🇸
OHSU Knight Cancer Institute, Portland, Oregon, United States
🇺🇸
Portland VA Medical Center, Portland, Oregon, United States

Screening More Patients for Colorectal Cancer Through Adapting and Refining Targeted Evidence-Based Interventions in Rural Settings, SMARTER CRC

Not Applicable

Completed

Conditions: Colorectal Carcinoma

Interventions: Other: Fecal Immunochemical Test
Other: Interview
Behavioral: Patient Navigation

First Posted Date: 2021-05-18

Last Posted Date: 2024-12-09

Lead Sponsor: OHSU Knight Cancer Institute

Target Recruit Count: 15510

Registration Number: NCT04890054

Locations: 🇺🇸
OHSU Knight Cancer Institute, Portland, Oregon, United States

Venetoclax, Dasatinib, Prednisone, Rituximab and Blinatumomab for the Treatment of Newly Diagnosed or Relapsed Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia or Mixed Phenotype Acute Leukemia

Phase 1

Recruiting

Conditions: B Acute Lymphoblastic Leukemia
B Acute Lymphoblastic Leukemia With t(9;22)(q34.1;q11.2); BCR-ABL1
Recurrent B Acute Lymphoblastic Leukemia
Mixed Phenotype Acute Leukemia
Recurrent Mixed Phenotype Acute Leukemia

Interventions: Drug: Dasatinib
Drug: Methotrexate
Drug: Prednisone
Biological: Rituximab
Drug: Venetoclax
Biological: Blinatumomab
Procedure: Bone Marrow Aspiration and Biopsy
Procedure: Lumbar Puncture
Procedure: Biospecimen Collection

First Posted Date: 2021-05-05

Last Posted Date: 2025-03-06

Lead Sponsor: OHSU Knight Cancer Institute

Target Recruit Count: 20

Registration Number: NCT04872790

Locations: 🇺🇸
OHSU Knight Cancer Institute, Portland, Oregon, United States

Isatuximab, Carfilzomib, and Pomalidomide for the Treatment of Relapsed or Refractory Multiple Myeloma

Phase 2

Active, not recruiting

Conditions: Recurrent Plasma Cell Myeloma
Refractory Plasma Cell Myeloma

Interventions: Drug: Carfilzomib
Biological: Isatuximab
Drug: Pomalidomide

First Posted Date: 2021-04-20

Last Posted Date: 2024-12-05

Lead Sponsor: OHSU Knight Cancer Institute

Target Recruit Count: 5

Registration Number: NCT04850599

Locations: 🇺🇸
OHSU Knight Cancer Institute, Portland, Oregon, United States

A Digital Intervention Protocol to Enhance Recovery After Head and Neck Surgery

Not Applicable

Completed

Conditions: Head and Neck Carcinoma

Interventions: Device: Fitbit
Device: Virtual Reality Device
Other: Questionnaire Administration

First Posted Date: 2021-03-24

Last Posted Date: 2022-10-13

Lead Sponsor: OHSU Knight Cancer Institute

Target Recruit Count: 80

Registration Number: NCT04814524

Locations: 🇺🇸
OHSU Knight Cancer Institute, Portland, Oregon, United States

Virtual Reality Experiences for Anxiety and Pain Control

Not Applicable

Completed

Conditions: Malignant Solid Neoplasm
Hematopoietic and Lymphoid Cell Neoplasm

Interventions: Other: Survey Administration
Procedure: Virtual Reality Game
Procedure: Virtual Reality Meditation

First Posted Date: 2021-02-18

Last Posted Date: 2022-09-07

Lead Sponsor: OHSU Knight Cancer Institute

Target Recruit Count: 32

Registration Number: NCT04759183

Locations: 🇺🇸
OHSU Knight Cancer Institute, Portland, Oregon, United States

Pemigatinib After Chemotherapy for the Treatment of Newly Diagnosed Acute Myeloid Leukemia

Phase 1

Recruiting

Conditions: Acute Myeloid Leukemia

Interventions: Procedure: Biospecimen Collection
Procedure: Bone Marrow Aspirate
Procedure: Bone Marrow Biopsy
Drug: Cytarabine
Drug: Daunorubicin
Procedure: Electrocardiography
Drug: Pemigatinib

First Posted Date: 2020-12-09

Last Posted Date: 2024-12-10

Lead Sponsor: OHSU Knight Cancer Institute

Target Recruit Count: 32

Registration Number: NCT04659616

Locations: 🇺🇸
UT Southwestern/Simmons Cancer Center-Dallas, Dallas, Texas, United States
🇺🇸
OHSU Knight Cancer Institute, Portland, Oregon, United States

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy